Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Instagram Outage Disrupts Thousands of U.S. Users 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the following investor conferences in September:
- 12th Annual Wells Fargo Securities Healthcare Conference in Boston on Wednesday, September 6, 2017 at 10:50 a.m. Eastern Time (ET);
- Morgan Stanley Global Healthcare Conference in New York City on Wednesday, September 13, 2017 at 11:40 a.m. ET; and
- Cantor Fitzgerald Global Healthcare Conference in New York City on Tuesday, September 26, 2017 at 1:05 p.m. ET.
The presentations will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis. To learn more, please visit: www.globalbloodtx.com and follow the company on Twitter: @GBT_News.
Contact Information: Myesha Lacy (investors) GBT 650-351-4730 [email protected] Julie Normart (media) Pure Communications 415-946-1087 [email protected]
